192 related articles for article (PubMed ID: 35772635)
1. Synthesis and biological evaluation of niclosamide PROTACs.
Munoz E; Chen G; Hossain A; Wu S; Oceguera Nava E; Hang J; Lee T; Zhang Q; Wang G; Chen QH
Bioorg Med Chem Lett; 2022 Sep; 72():128870. PubMed ID: 35772635
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
3. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
4. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
5. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang X; Luukkonen LM; Eissler CL; Crowley VM; Yamashita Y; Schafroth MA; Kikuchi S; Weinstein DS; Symons KT; Nordin BE; Rodriguez JL; Wucherpfennig TG; Bauer LG; Dix MM; Stamos D; Kinsella TM; Simon GM; Baltgalvis KA; Cravatt BF
J Am Chem Soc; 2021 Apr; 143(13):5141-5149. PubMed ID: 33783207
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models.
Gockel LM; Pfeifer V; Baltes F; Bachmaier RD; Wagner KG; Bendas G; Gütschow M; Sosič I; Steinebach C
Arch Pharm (Weinheim); 2022 May; 355(5):e2100467. PubMed ID: 35128717
[TBL] [Abstract][Full Text] [Related]
7. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
8. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
10. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
[TBL] [Abstract][Full Text] [Related]
11. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
12. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
14. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
15. PROTACs in the Management of Prostate Cancer.
Yedla P; Babalghith AO; Andra VV; Syed R
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175108
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes.
Zhang L; Riley-Gillis B; Vijay P; Shen Y
Mol Cancer Ther; 2019 Jul; 18(7):1302-1311. PubMed ID: 31064868
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
20. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
